Daiichi Sankyo reports Q2 fiscal year 2026 financial results
Revenue rose 19.7% to 1.167 trillion yen driven by Enhertu and Datroway sales growth while FY2026 guidance remains unchanged.
See the latest news and media coverage for Daiichi Sankyo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company
daiichisankyo.comLast updated
In short: Daiichi Sankyo applied to expand Enhertu's Japanese use to uterine carcinosarcoma.
Revenue rose 19.7% to 1.167 trillion yen driven by Enhertu and Datroway sales growth while FY2026 guidance remains unchanged.
The DESTINY-Breast05 trial found a 53% lower risk of invasive recurrence or death versus T-DM1; AstraZeneca will pay Daiichi Sankyo a $75 million milestone.
The TROP2-directed ADC treats metastatic triple-negative breast cancer with improved survival.
Approval based on DESTINY-Breast05 results showing 53% reduced recurrence risk. It marks the fifth Enhertu approval in less than a year.
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...
Daiichi Sankyo announced on the 30th that its core operating profit for the April-September 2026 fiscal year (first half) increased by 47% year-on-year to 221.3 billion yen. Growth was driven by its key cancer drugs, Enhertu and Trodelvy, as well as the weaker yen...
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence...
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for first-line metastatic triple-negative bre...
Track Daiichi Sankyo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Daiichi Sankyo and other trending companies.